BridgeMD
New treatment option for Liver Elastography
Official title Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ClinicalTrials.gov ID: NCT07400367
What this study is testing
- What it's testing
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the new clinical term introduced in 2023 to redefine what was formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD). It is defined as fatty liver confirmed by imaging or biopsy, accompanied by at least one cardiometabolic risk factor (e.g., hyperglycemia, dyslipidemia, hypertension, or obesity).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- ALT ≥ 60 U/L
- Liver steatosis identified by ultrasound
- Meet at least one cardiometabolic criteria:
- BMI ≥ 25 kg/m2 (Asian ≥23)
- Waist circumference: \> 94cm (M) 80cm(F)
You likely can't join if
- HBsAg(+)
- Anti-HCV (+)
- Cirrhosis
- Excessive alcohol intake ( Male over 210g/wk; Female over 140mg/wk)
- Could not rule out Autoimmune hepatitis (ANA, or AMA or ASMA (+))
- Could not rule out drug related hepatitis
See the full eligibility criteria
- ALT ≥ 60 U/L
- Liver steatosis identified by ultrasound
- Meet at least one cardiometabolic criteria:
- BMI ≥ 25 kg/m2 (Asian ≥23)
- Waist circumference: \> 94cm (M) 80cm(F)
- Fasting blood glucose ≥ 100 mg/dL
- HbA1c ≥ 5.7
- Receiving treatment of diabetes
- Receiving treatment of Hypertension
- Average home blood pressure: ≥ 130/85 mmHg
- TG ≥ 150 mg/dL
- HDL ≤ 40 mg/dL
- Receiving treatment of dyslipidemia
- HBsAg(+)
- Anti-HCV (+)
- Cirrhosis
- Excessive alcohol intake ( Male over 210g/wk; Female over 140mg/wk)
- Could not rule out Autoimmune hepatitis (ANA, or AMA or ASMA (+))
- Could not rule out drug related hepatitis
- Receiving drug that might induce liver steatosis:
- Glucocorticoids
- Amiodarone
- Tamoxifen
- Methotrexate
- Valproate
- Tetracycline
- Chemotherapeutic agents
- Receiving immune modulators or biologics
- Receiving antibiotics within 1 month
- Receiving any cancer treatment
- Have diagnosis of "Catastrophic Illness" defined by Health Administration of Taiwan
- eGFR\<60
- Pregnancy
- Currently enrolled in other dietary or pharmacology clinical trial
The study team makes the final eligibility decision.
Where it's taking place
- New Taipei City, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Taipei City, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.